Literature DB >> 322771

[Long-term therapy using horse anti-dog lymphocyte globulin without sensitization against horse protein].

J Scheel, K H Duswald, J Ring, J Seifert, S Scholz, W Brendel.   

Abstract

Eight mongrel dogs received a standard daily i.v. infusion of 20 mg/kg b.w. deaggregated horse-anti-dog-lymphocyte-globulin (ALG) and additional prednisolone (1 mg/kg b.w. daily i.v.) over a maximum period of 82 days following pretreatment with deaggregated normal horse IgG. No sensitization against horse protein was observed during therapy of afterwards as proved by lack of humoral antibodies against horse antigens, maintained lymphopenia, good compatibility, longterm prolongation of xenogeneic skin graft survival (85.6+/-20.6 days, n=8' untreated controls 12.5+/-1.3 days, n=4) and longterm suppression of cytotoxic antibodies against donor lymphocytes. The level of preformed agglutinating antibodies against horse erythrocytes was significantly reduced, while preformed antibodies against other species remained normal. The immune response to a challenge injection of anti-lymphocyte-serum (ALS) 6-11 weeks after termination of treatment was significantly lower in the ALG treated animals as compared to the control group. These results suggest the involvement of a specific mechanism of unresponsiveness against ALG other than immunosuppression only. It is concluded, that by the described method sensitization against ALG can be prevented during longterm treatment.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 322771     DOI: 10.1007/bf00996207

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  26 in total

1.  INDUCTION OF IMMUNOLOGICAL PARALYSIS IN TWO ZONES OF DOSAGE.

Authors:  N A MITCHISON
Journal:  Proc R Soc Lond B Biol Sci       Date:  1964-12-15

2.  Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.

Authors:  E M Lance; M Kremer; J Abbosh; V E Jones; S Knight; P B Medawar
Journal:  Clin Exp Immunol       Date:  1975-07       Impact factor: 4.330

3.  Diffusion-in-gel methods for immunological analysis. II.

Authors:  O OUCHTERLONY
Journal:  Prog Allergy       Date:  1962

4.  Specific unresponsiveness to skin allografts in mice. 3. Synergistic effect of tissue extracts, Bordetella pertussis, and antilymphocytic serum.

Authors:  M Pinto; L Brent; A V Thomas
Journal:  Transplantation       Date:  1974-05       Impact factor: 4.939

5.  Induction of tolerance to horse gamma globulin (HoGG) and antilymphocyte globulin (HoALG) in humans and experimental animals.

Authors:  H Gewurz; A W Moberg; D Johnson; R L Simmons; J S Najarian
Journal:  Transplant Proc       Date:  1971-03       Impact factor: 1.066

6.  Serology and genetics of the DL-A system. I. Establishment of specificities.

Authors:  E D Albert; V M Erickson; T C Graham; M Parr; J W Templeton; M R Mickey; E D Thomas; R Storb
Journal:  Tissue Antigens       Date:  1973

7.  [The risk of ALG therapy possible side effects: prevention and treatment (author's transl)].

Authors:  J Ring; J Seifert; G Lob; W Land; K Coulin; W Brendel
Journal:  Klin Wochenschr       Date:  1973-05-15

8.  [Surprising results of intravenous therapy using antilymphocyte serum in organ transplantations].

Authors:  W Brendel; W Land
Journal:  Dtsch Med Wochenschr       Date:  1968-11-29       Impact factor: 0.628

9.  Further experiments on the action of antilymphocytic antiserum.

Authors:  R H Levey; P B Medawar
Journal:  Proc Natl Acad Sci U S A       Date:  1967-08       Impact factor: 11.205

10.  [Immunological tolerance].

Authors:  U Hopf
Journal:  Klin Wochenschr       Date:  1971-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.